BCR/ABL promotes dendritic cell-mediated natural killer cell activation

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• The BCR/ABL fusion gene drives chronic myelogenous leukemia (CML) and influences natural killer (NK) cell recognition.
• Allogeneic NK cells are implicated in graft-versus-leukemia effects, but NK cell activation regulation in this context is unclear.

Purpose of the Study:

• To investigate the role of dendritic cells (DCs) in NK cell activation within the context of CML.
• To elucidate the mechanisms underlying DC-mediated NK cell activation in BCR/ABL-positive CML.

Main Methods:

• Generation of CML patient-derived DCs and assessment of their NK cell stimulatory capacity in vitro.
• Gene transfer in mouse bone marrow progenitors to study the necessity of ABL/ABL in DC-mediated NK cell activation.
• Analysis of NKG2D receptor involvement and the effect of imatinib mesylate on DC-NK cell cross-talk.

Main Results:

• CML patient-derived DCs exhibit selective NK cell stimulatory capacity.
• ABL/ABL is essential for promoting DC-mediated NK cell activation, a function not observed in other myeloproliferative disorders.
• NK cell activation involves NKG2D receptors and is inhibited by imatinib mesylate, which reduces NKG2D ligand expression on DCs.

Conclusions:

• Clonal BCR/ABL DCs possess a unique ability to activate NK cells, potentially contributing to CML control.
• Imatinib mesylate interferes with DC-mediated NK cell activation, suggesting a potential negative impact on graft-versus-leukemia responses at the DC level.